Wealth Enhancement Advisory Services LLC Has $12.60 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,348 shares of the company’s stock after buying an additional 607 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in AstraZeneca were worth $12,603,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AZN. LPL Financial LLC boosted its stake in shares of AstraZeneca by 11.2% in the 2nd quarter. LPL Financial LLC now owns 539,191 shares of the company’s stock valued at $42,052,000 after purchasing an additional 54,345 shares in the last quarter. Johnson Investment Counsel Inc. boosted its stake in shares of AstraZeneca by 11.0% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 7,144 shares of the company’s stock valued at $557,000 after purchasing an additional 709 shares in the last quarter. Main Street Financial Solutions LLC acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at $227,000. Meeder Advisory Services Inc. acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at $206,000. Finally, GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at $26,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $67.01 on Monday. The stock has a market capitalization of $207.77 billion, a P/E ratio of 32.06, a P/E/G ratio of 1.19 and a beta of 0.46. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average price of $66.11 and a two-hundred day moving average price of $74.86.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 EPS. Equities analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca has a consensus rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.